Eisai Introduces first-in-Class Epilepsy Treatment Fycompa in India
by Shrutee K/DNS
Mumbai: 22nd August, 2017 Eisai
Pharmaceuticals India Pvt. Ltd, a leading Japanese pharmaceutical company announced the launch of Fycompa (perampanel), a new anti-epileptic drug.
Approved in more
than 55 countries worldwide, Fycompa is indicated as an adjunctive
therapy for the treatment of partial-onset seizures (POS) with or without
secondarily generalized seizures in patients with epilepsy aged 12 and older.
Fycompa is first
in class in-house developed anti-epileptic drug, available in tablet form as a
once-daily oral dose.
“Nearly 12 million
patients in India suffer from epilepsy and 95% of these patients do not receive
adequate treatment. Abiding by our core philosophy of human health care we
strive to change this by developing a drug that can significantly improve the
quality of life of epileptic patients and give them hope to live a seizure
free-life,” said Mr. Sanjit Singh Lamba,
Managing Director, Eisai Pharmaceuticals India.”
He
further added,
“Epilepsy has been a therapeutic focus area for Eisai and we will continue to
use our strengths in research and development to create drugs that will improve
and enhance the quality of life.”
Adding
to this Dr. Manoj Malhotra – Head of Medical Affairs, Americas Region, Global
Head of Epilepsy Medical Affairs, Neurology Business Group, Eisai Inc. said “With the launch
of many anti-epileptic drugs in the last decade we have seen a significant
improvement in seizure freedom rate. However, almost 30-40% of the seizures
remain poorly controlled leading to low compliance. Fycompa will help to
address these key therapeutic challenges and improve patient outcomes”.
Commenting on the
low awareness on epilepsy, Mr. Saumil
Mody- Vice President, Commercial Operations, Eisai India Ltd. said
“Treatment outcomes for epilepsy are very low because we are dealing with very
challenging circumstances, a majority of epilepsy cases go undiagnosed because
of numerous factors like the social stigma associated with the disease, lack of
awareness of the symptoms particularly in rural India. Our aim is to address
these challenges and enable epileptic patients and their families to live a
seizure-free life.”
Epilepsy is a
condition that affects the brain and causes repeated seizures. Approximately 50
million people worldwide have epilepsy, making it one of the most common
neurological diseases globally.
About
Eisai Pharmaceuticals India Pvt. Ltd.
Eisai
Pharmaceuticals India Pvt. Ltd is a subsidiary of Eisai Co., Ltd., a leading
global research and development-based pharmaceutical company headquartered in
Japan. We define our corporate mission as “giving first thought to patients and
their families and to increasing the benefits health care provides,” which we
call our Human health care (hhc)
philosophy. With approximately 10,000 employees working across our global
network of R&D facilities, manufacturing sites and marketing subsidiaries,
we strive to realize our hhc
philosophy by delivering innovative products in various therapeutic areas with
high unmet medical needs, including Neurology and Oncology. As a global
pharmaceutical company, our mission extends to patients around the world
through our investment and participation in partnership-based initiatives to
improve access to medicines in developing and emerging countries. For more
information about Eisai Co., Ltd., please visit www.eisai.com
Comments
Post a Comment